Article type: Letter to Editor
Article title: Anticalcitonin gene-related peptide monoclonal antibodies: an overview
Journal: APIK
Journal of Internal Medicine
Year: 2020
Authors: Jamir Pitton Rissardo, Ana Letícia Fornari
Caprara
E-mail: jamirrissardo@gmail.com
ABSTRACT
Headaches substantially affect the quality of life, causing disability in patients. In this context, migraine is a primary headache disorder that can occur episodic or chronic. The development of new therapies for this disease was limited throughout the years; first, the oral medication; after that occurred the approval of botulinum toxin. In 2018, the anticalcitonin gene-related peptide (anti-CGRP) monoclonal antibodies were available. Here, we would like to do a table with the other anti-CGRP antibodies already approved by the Food and Drug Administration that together with the study of Goel could lead to a better comprehension of the management of this group of medications.
Keywords: Anticalcitonin gene-related peptide monoclonal antibodies, headache, therapy, erenumab, fremanezumab
Full text available at:
DOI
10.4103/AJIM.AJIM_70_19
Citation
Rissardo
JP, Fornari Caprara AL. Anticalcitonin gene-related
peptide monoclonal antibodies: an overview. APIK J Int Med 2020;8:33-4
